

REMARKS

Pursuant to C.F.R. § 1.312, Applicants have amended the specification so that the last sentence of the paragraph beginning at page 29, line 26, is complete. Support for this amendment can be found, for example, at page 22, ll. 11-19, of the application as filed, which describes headgroup modified lipids. Applicants have deleted the text at lines 1-2 of page 31 for clarity. Applicants also have amended the first full paragraph of page 31 for clarity. Support for this amendment can be found, for example, in examples 11 of the specification, which describes the detection of transfection activity of a pEGFP-C1 plasmid. Accordingly, no new matter has been added by these amendments. Entry of these amendments is respectfully solicited.

This amendment is being submitted prior to payment of the issue fee and further pursuant to the Examiner's telephone call of June 24, 2008, indicating that the Publications Branch found page 30 of the specification missing from the as-filed papers. Applicants note that the subject matter of page 30, which was inadvertently omitted upon filing of the present application, is present at page 28, line 5, to page 30, line 3, of Provisional Application no. 60/122,365 (copies of these pages are attached), to which the present application claims priority. Applicants further note that the presently allowed claims were examined without consideration of the disclosure of page 30. Accordingly, applicants submit that the application is in condition for issuance.

The Examiner is invited to call the undersigned at 617-832-1223 with any questions or comments. Please charge any additional fees required to enter this amendment, or credit any overpayment, to **Deposit Account No. 06-1448, TRA-016.01**.

Dated: June 26, 2008

Respectfully submitted,

/Hilary Dorr Lang/

Hilary Dorr Lang

Registration No.: 51,917

FOLEY HOAG LLP

155 Seaport Blvd

Boston, Massachusetts 02210

(617) 832-1223

Attorney for Applicants